▁Ch 6.50390625
iros 9.8828125
cience 1.498046875
▁Group 5.8359375
▁pl 5.0234375
c 0.0028972625732421875
, 2.48828125
▁a 1.33984375
▁ren 8.125
owned 0.069580078125
▁ph 4.625
arma 0.11114501953125
ce 0.046234130859375
ut 0.0002982616424560547
ical 0.000431060791015625
▁research 2.982421875
▁and 0.609375
▁development 0.1260986328125
▁company 0.380859375
▁based 2.939453125
▁in 0.05328369140625
▁Cambridge 3.443359375
, 0.265380859375
▁England 2.46484375
, 0.2474365234375
▁has 1.1376953125
▁set 6.3828125
▁its 1.7001953125
▁s 0.1925048828125
ights 0.0011262893676757812
▁on 0.064453125
▁a 2.572265625
▁potential 3.720703125
▁break 2.00390625
through 0.0095062255859375
▁in 0.82666015625
▁ant 6.3359375
ican 2.552734375
cer 0.0004544258117675781
▁treatment 1.8544921875
. 0.677734375
▁The 1.455078125
▁company 0.39208984375
▁has 1.091796875
▁successfully 4.05859375
▁identified 3.0390625
▁and 2.482421875
▁synth 2.630859375
es 0.00909423828125
ized 0.278076171875
▁two 3.443359375
▁novel 1.6328125
▁comp 1.400390625
ounds 0.00583648681640625
▁that 0.76171875
▁exhib 2.947265625
it 0.00609588623046875
▁prom 2.767578125
ising 0.0005788803100585938
▁effic 4.55859375
acy 0.000598907470703125
▁against 0.8310546875
▁various 2.11328125
▁types 0.66259765625
▁of 0.002262115478515625
▁cancer 0.1346435546875
▁cells 0.904296875
▁in 2.0625
▁pre 1.2421875
cl 0.277099609375
in 1.8596649169921875e-05
ical 0.0001575946807861328
▁studies 0.54931640625
. 0.1365966796875
▁With 3.998046875
▁further 2.078125
▁assess 7.26953125
ment 0.1651611328125
▁and 0.68115234375
▁evaluation 3.3125
▁in 3.5859375
▁human 2.62109375
▁tri 1.037109375
als 6.902217864990234e-05
, 0.06341552734375
▁Ch 2.43359375
iros 0.005611419677734375
cience 0.0005922317504882812
▁hopes 4.17578125
▁to 0.0219879150390625
▁contribute 6.63671875
▁significantly 2.1484375
▁to 0.070068359375
▁the 0.1385498046875
▁fight 1.283203125
▁against 0.000507354736328125
▁cancer 0.08978271484375
▁and 2.025390625
▁provide 2.90625
▁hope 2.169921875
▁to 0.6787109375
▁patients 0.81103515625
▁world 0.91796875
wide 0.00013554096221923828
. 0.035980224609375
<0x0A> 0.1527099609375
The 1.689453125
▁first 3.525390625
▁comp 0.257080078125
ound 0.00016677379608154297
, 0.30078125
▁CS 2.6953125
- 0.76611328125
1 1.1806640625
2 2.490234375
4 2.830078125
, 0.70849609375
▁is 1.2802734375
▁a 0.2119140625
▁small 2.490234375
▁mole 0.123046875
c 0.004039764404296875
ule 1.5735626220703125e-05
▁that 0.43408203125
▁has 1.6533203125
▁shown 0.94482421875
▁considerable 4.71484375
▁in 3.25390625
hib 0.0657958984375
itory 0.446533203125
▁effects 1.1240234375
▁on 0.199951171875
▁tum 2.48828125
or 0.0750732421875
▁growth 0.60791015625
▁in 1.14453125
▁pre 2.205078125
cl 0.048187255859375
in 3.814697265625e-06
ical 0.00010859966278076172
▁models 1.2744140625
. 0.4951171875
▁Target 8.0078125
ing 0.2335205078125
▁specific 3.06640625
▁signal 2.48828125
ing 0.0135650634765625
▁path 0.039459228515625
ways 0.0011243820190429688
▁involved 1.4072265625
▁in 0.00046563148498535156
▁the 1.892578125
▁pro 1.4296875
gression 1.7919921875
▁of 0.2154541015625
▁cancer 0.209228515625
, 0.37841796875
▁CS 0.18359375
- 0.0007939338684082031
1 0.0010538101196289062
2 0.0003204345703125
4 0.00038504600524902344
▁imp 7.6640625
edes 0.35107421875
▁the 0.52685546875
▁formation 3.310546875
▁and 1.775390625
▁pro 1.435546875
l 0.185302734375
ifer 7.033348083496094e-06
ation 7.605552673339844e-05
▁of 0.0002765655517578125
▁cancer 0.986328125
▁cells 0.1068115234375
. 1.50390625
▁In 1.7177734375
▁labor 5.27734375
atory 0.0007843971252441406
▁experiments 1.3671875
, 0.08685302734375
▁it 2.736328125
▁has 0.595703125
▁exhib 3.44921875
ited 0.00012981891632080078
▁particular 5.59765625
▁effect 2.087890625
iveness 0.002777099609375
▁against 0.30908203125
▁lung 3.1484375
▁and 1.55859375
▁breast 1.181640625
▁cancer 0.1981201171875
▁cells 0.411376953125
, 0.69873046875
▁both 5.48828125
▁of 0.1912841796875
▁which 0.0012407302856445312
▁are 0.26123046875
▁pre 3.34375
val 0.018646240234375
ent 0.0005755424499511719
▁and 1.32421875
▁challeng 1.6640625
ing 6.0439109802246094e-05
▁to 0.375
▁treat 0.0243682861328125
▁effectively 4.22265625
. 0.07293701171875
▁Under 8.90625
lying 4.94140625
▁the 1.029296875
▁comp 2.4609375
ound 0.009735107421875
' 0.625
s 7.843971252441406e-05
▁success 2.4375
▁is 0.391357421875
▁its 0.31982421875
▁unique 1.9619140625
▁ability 2.0
▁to 0.0008792877197265625
▁bind 2.79296875
▁to 0.2022705078125
▁a 1.8623046875
▁critical 4.2421875
▁protein 1.23046875
▁involved 1.474609375
▁in 0.00037550926208496094
▁cancer 1.189453125
▁cell 0.70361328125
▁surv 2.111328125
ival 0.00019657611846923828
▁and 0.8193359375
▁promote 5.62109375
▁their 2.251953125
▁death 0.78076171875
, 1.5732421875
▁a 2.3203125
▁mechanism 2.16796875
▁that 0.480712890625
▁sets 2.841796875
▁it 0.08587646484375
▁apart 0.0012159347534179688
▁from 0.0009889602661132812
▁existing 1.794921875
▁treatment 3.509765625
▁options 0.0582275390625
. 0.0484619140625
<0x0A> 0.181396484375
Build 6.390625
ing 0.0026531219482421875
▁upon 2.92578125
▁these 2.64453125
▁prom 0.603515625
ising 6.604194641113281e-05
▁results 0.57861328125
, 0.015533447265625
▁Ch 0.224853515625
iros 0.00125885009765625
cience 9.298324584960938e-05
▁research 5.359375
ers 0.0116729736328125
▁have 0.373046875
▁also 1.806640625
▁un 4.3046875
cover 0.1915283203125
ed 8.106231689453125e-06
▁a 0.810546875
▁potential 3.916015625
▁imm 6.98828125
un 0.466552734375
other 0.453857421875
apy 0.71142578125
▁candidate 2.3359375
, 0.6845703125
▁CS 0.267822265625
- 0.005992889404296875
1 0.415283203125
7 3.384765625
2 2.189453125
, 0.52587890625
▁that 1.0751953125
▁could 3.056640625
▁revolution 2.7421875
ize 0.001049041748046875
▁the 0.5908203125
▁landscape 4.78515625
▁of 0.0284271240234375
▁cancer 0.133056640625
▁treatment 0.198486328125
. 0.0565185546875
▁Im 5.92578125
mun 0.055999755859375
other 0.0023326873779296875
apy 0.263427734375
, 2.220703125
▁which 0.50390625
▁har 1.158203125
ness 4.649162292480469e-06
es 0.00011074542999267578
▁the 0.0243988037109375
▁body 0.60302734375
' 0.0023326873779296875
s 1.3470649719238281e-05
▁imm 0.30224609375
une 0.00010406970977783203
▁system 0.0098419189453125
▁to 0.01020050048828125
▁target 2.08984375
▁and 0.138427734375
▁destroy 0.6962890625
▁cancer 0.0811767578125
▁cells 0.053192138671875
, 0.002941131591796875
▁has 0.460205078125
▁emer 1.3720703125
ged 0.0001062154769897461
▁as 0.0058135986328125
▁a 0.1788330078125
▁ground 4.16796875
bre 0.06298828125
aking 7.152557373046875e-07
▁approach 0.337890625
▁in 0.9580078125
▁recent 0.53173828125
▁years 0.017547607421875
. 0.59375
▁CS 2.458984375
- 0.0003361701965332031
1 0.0005273818969726562
7 0.00446319580078125
2 0.0006074905395507812
, 1.30859375
▁when 5.51953125
▁admin 1.6318359375
ister 1.0132789611816406e-05
ed 3.3020973205566406e-05
▁in 1.1279296875
▁pre 3.39453125
cl 0.02685546875
in 2.002716064453125e-05
ical 0.00013113021850585938
▁studies 1.75390625
, 0.0252532958984375
▁was 2.43359375
▁found 0.92919921875
▁to 0.002040863037109375
▁stim 2.126953125
ulate 6.103515625e-05
▁imm 3.240234375
une 0.042327880859375
▁cells 0.96484375
▁and 1.88671875
▁promote 2.35546875
▁their 0.73388671875
▁ability 2.46875
▁to 0.00031948089599609375
▁identify 3.404296875
▁and 0.036285400390625
▁attack 1.9619140625
▁cancer 0.247314453125
▁cells 0.052520751953125
, 0.95751953125
▁effectively 3.458984375
▁bol 5.38671875
ster 4.5180320739746094e-05
ing 8.71419906616211e-05
▁the 0.1982421875
▁imm 1.4384765625
une 0.03375244140625
▁response 0.92919921875
▁against 0.8095703125
▁tum 1.22265625
ors 0.153076171875
. 0.021881103515625
▁This 1.9716796875
▁comp 3.328125
ound 0.0015001296997070312
, 2.921875
▁if 2.86328125
▁successful 1.28125
, 1.6357421875
▁could 0.328857421875
▁provide 1.9228515625
▁an 1.9931640625
▁alternative 1.6416015625
▁treatment 2.25390625
▁strategy 3.240234375
▁for 0.52734375
▁patients 0.338134765625
▁who 0.9150390625
▁have 1.0107421875
▁limited 3.990234375
▁options 0.787109375
▁due 2.4296875
▁to 0.0001068115234375
▁their 2.35546875
▁disease 2.49609375
' 0.70849609375
s 0.00019049644470214844
▁nature 3.583984375
▁or 0.250244140625
▁pro 1.982421875
gression 0.13232421875
. 0.11614990234375
<0x0A> 0.0261993408203125
Ex 6.1015625
c 0.451904296875
iting 0.6201171875
▁as 5.31640625
▁these 0.29052734375
▁pre 3.923828125
cl 0.5634765625
in 3.910064697265625e-05
ical 4.5180320739746094e-05
▁data 3.84375
▁might 6.17578125
▁be 0.1090087890625
, 0.0112457275390625
▁the 1.8515625
▁ult 3.591796875
imate 0.0002332925796508789
▁validation 2.919921875
▁lies 4.3515625
▁in 0.053009033203125
▁human 0.8486328125
▁tri 0.263427734375
als 7.62939453125e-06
. 0.50341796875
▁Ch 0.8251953125
iros 0.001956939697265625
cience 3.7550926208496094e-05
▁Group 2.375
▁pl 0.95263671875
c 1.3828277587890625e-05
▁is 0.7138671875
▁eager 3.595703125
▁to 0.2447509765625
▁progress 2.685546875
▁the 2.1171875
▁comp 1.3427734375
ounds 0.0101470947265625
▁to 1.3662109375
▁the 1.1416015625
▁next 0.6279296875
▁stage 0.3251953125
, 1.779296875
▁subject 4.52734375
ing 0.0986328125
▁them 0.09295654296875
▁to 0.0042724609375
▁rig 1.1875
orous 0.0013246536254882812
▁testing 1.3896484375
▁in 0.9404296875
▁clin 0.65478515625
ical 0.00434112548828125
▁tri 0.34619140625
als 5.364418029785156e-06
▁to 1.0966796875
▁assess 1.533203125
▁their 0.038787841796875
▁safety 0.49658203125
▁and 0.412841796875
▁effic 0.10955810546875
acy 1.4662742614746094e-05
▁in 0.60693359375
▁human 3.482421875
▁volunte 4.765625
ers 0.00269317626953125
. 0.05682373046875
▁The 1.2978515625
▁company 0.330810546875
▁plans 3.7890625
▁to 0.0087890625
▁initi 2.025390625
ate 2.9325485229492188e-05
▁these 2.01953125
▁tri 0.360595703125
als 1.239776611328125e-05
▁within 2.8359375
▁the 0.133056640625
▁next 0.1912841796875
▁few 1.265625
▁months 1.66796875
▁pending 9.0859375
▁regul 0.7119140625
atory 0.00017690658569335938
▁appro 0.034423828125
val 1.6927719116210938e-05
s 0.95458984375
▁and 1.7490234375
▁sufficient 5.0078125
▁fund 0.3544921875
ing 0.011566162109375
, 2.130859375
▁with 1.65625
▁hopes 4.04296875
▁of 0.371337890625
▁rec 6.2890625
ruit 0.0004127025604248047
ing 0.003936767578125
▁a 3.017578125
▁diverse 1.560546875
▁coh 2.388671875
ort 2.384185791015625e-06
▁of 0.049224853515625
▁patients 0.77197265625
▁representing 4.49609375
▁different 1.455078125
▁cancer 1.2607421875
▁types 0.0859375
. 1.275390625
▁The 2.392578125
▁trial 4.16796875
▁design 2.923828125
▁will 0.732421875
▁follow 3.669921875
▁the 1.328125
▁highest 3.306640625
▁scientific 2.375
▁standards 0.68701171875
▁and 0.984375
▁ad 2.427734375
here 0.00440216064453125
▁to 0.029937744140625
▁string 3.12890625
ent 0.00014793872833251953
▁eth 0.64794921875
ical 0.00982666015625
▁consider 3.44140625
ations 4.0531158447265625e-06
, 0.8017578125
▁ens 0.7392578125
uring 4.661083221435547e-05
▁patients 5.2890625
' 0.1826171875
▁w 3.20703125
elf 3.0994415283203125e-06
are 2.562999725341797e-05
▁and 0.44873046875
▁the 3.22265625
▁reli 5.33203125
ability 0.0006804466247558594
▁of 0.0158843994140625
▁the 0.2177734375
▁obtained 6.77734375
▁data 0.2158203125
. 0.01265716552734375
<0x0A> 0.1129150390625
" 3.0546875
We 0.640625
▁are 0.24609375
▁genu 7.5859375
in 0.003505706787109375
ely 2.86102294921875e-06
▁excited 0.81884765625
▁about 0.39794921875
▁the 0.55224609375
▁potential 0.34814453125
▁of 0.276123046875
▁these 0.33251953125
▁two 1.3515625
▁comp 0.396240234375
ounds 0.00028204917907714844
," 1.6630859375
▁said 0.77392578125
▁Dr 1.0146484375
. 0.05804443359375
▁Emma 6.90625
▁Johnson 6.48828125
, 0.0291290283203125
▁CE 1.9375
O 6.0439109802246094e-05
▁of 0.1689453125
▁Ch 0.012786865234375
iros 0.00048422813415527344
cience 6.973743438720703e-05
▁Group 0.1488037109375
▁pl 0.10760498046875
c 7.62939453125e-06
, 2.234375
▁during 3.896484375
▁a 0.423095703125
▁recent 0.277099609375
▁press 1.619140625
▁conference 0.30029296875
. 0.0762939453125
▁She 5.375
▁emphas 1.482421875
ized 0.0030193328857421875
▁the 0.6943359375
▁ur 2.423828125
gent 0.266845703125
▁need 0.021575927734375
▁for 0.1661376953125
▁novel 1.7470703125
▁th 2.34375
era 5.960464477539062e-07
pe 4.76837158203125e-07
ut 3.2186508178710938e-06
ic 0.15576171875
▁options 0.75048828125
▁to 1.337890625
▁combat 1.8916015625
▁the 1.5576171875
▁dev 2.044921875
ast 3.2186508178710938e-06
ating 0.0751953125
▁impact 0.77685546875
▁of 0.026275634765625
▁cancer 0.0086669921875
▁and 1.943359375
▁expressed 2.044921875
▁c 5.61328125
aut 0.0118560791015625
ious 0.00145721435546875
▁optim 0.022796630859375
ism 0.00012028217315673828
▁about 0.517578125
▁the 0.0767822265625
▁out 3.541015625
comes 0.2529296875
, 5.2265625
▁based 3.44140625
▁upon 6.97265625
▁the 0.435791015625
▁rig 6.9453125
orous 0.0271148681640625
▁pre 0.89111328125
cl 0.01047515869140625
in 0.00030732154846191406
ical 8.71419906616211e-05
▁screen 5.2265625
ing 0.0933837890625
▁of 3.564453125
▁the 0.5205078125
▁comp 0.2269287109375
ounds 0.0038394927978515625
. 0.36279296875
▁Dr 3.357421875
. 0.0015621185302734375
▁Johnson 0.027801513671875
▁also 1.5576171875
▁highlight 1.3046875
ed 0.00014793872833251953
▁the 0.09063720703125
▁collabor 4.72265625
ative 0.04217529296875
▁efforts 1.2431640625
▁with 2.31640625
▁other 2.5390625
▁research 1.5888671875
▁institutions 1.302734375
▁and 0.56640625
▁support 6.0234375
▁from 0.90673828125
▁various 2.55078125
▁fund 1.5068359375
ing 0.08349609375
▁organizations 1.8935546875
, 0.66943359375
▁acknowled 5.8359375
ging 0.0011510848999023438
▁the 0.4775390625
▁significance 3.052734375
▁of 0.01611328125
▁a 4.328125
▁collect 2.748046875
ive 0.0002608299255371094
▁commit 3.90625
ment 7.152557373046875e-06
▁to 0.321533203125
▁pushing 7.0546875
▁forward 1.46484375
▁the 0.76513671875
▁boundaries 1.2724609375
▁of 0.005115509033203125
▁medical 1.876953125
▁science 0.625
. 0.2763671875
<0x0A> 0.11737060546875
Wh 3.22265625
ile 0.00455474853515625
▁the 1.0732421875
▁road 3.22265625
▁from 4.91015625
▁pre 0.30322265625
cl 0.006916046142578125
in 3.063678741455078e-05
ical 0.00011050701141357422
▁research 2.03125
▁to 0.0081024169921875
▁approved 3.431640625
▁ther 1.4638671875
ap 0.6328125
ies 0.000232696533203125
▁is 0.625
▁length 4.5546875
y 0.0001519918441772461
▁and 0.147216796875
▁complex 2.6015625
, 0.00225067138671875
▁Ch 0.662109375
iros 0.00048422813415527344
cience 3.123283386230469e-05
▁Group 0.11688232421875
▁pl 0.0272064208984375
c 2.014636993408203e-05
' 3.779296875
s 0.00011646747589111328
▁commit 1.57421875
ment 0.00015592575073242188
▁to 0.057464599609375
▁adv 1.5703125
ancing 0.00403594970703125
▁these 2.533203125
▁potential 3.142578125
▁ant 3.724609375
ican 0.0016307830810546875
cer 0.0001138448715209961
▁comp 1.7783203125
ounds 0.00037789344787597656
▁is 0.68408203125
▁a 1.6376953125
▁g 6.09765625
lim 0.058074951171875
mer 1.5020370483398438e-05
▁of 0.0007839202880859375
▁hope 0.004673004150390625
▁for 0.1490478515625
▁cancer 2.333984375
▁patients 0.00930023193359375
▁and 1.5126953125
▁their 0.1695556640625
▁families 0.3125
▁world 0.9814453125
wide 2.4080276489257812e-05
. 0.01442718505859375
▁Should 5.68359375
▁the 0.65185546875
▁human 3.369140625
▁tri 0.048736572265625
als 3.933906555175781e-06
▁prove 0.68603515625
▁successful 0.09490966796875
, 0.05670166015625
▁these 1.2587890625
▁comp 0.434326171875
ounds 0.0001131296157836914
▁have 2.404296875
▁the 0.0079193115234375
▁potential 0.0081024169921875
▁to 0.0020008087158203125
▁join 5.640625
▁the 0.464111328125
▁ranks 0.7333984375
▁of 0.001476287841796875
▁ground 4.2578125
bre 0.045257568359375
aking 1.5497207641601562e-06
▁ther 1.9345703125
ap 0.0007877349853515625
ies 1.4424324035644531e-05
▁and 2.623046875
▁transform 2.669921875
▁the 0.14404296875
▁landscape 1.0712890625
▁of 0.0007004737854003906
▁cancer 0.0269317626953125
▁treatment 0.08026123046875
. 0.46728515625
▁As 2.955078125
▁st 8.7109375
ake 0.0399169921875
hold 0.0018405914306640625
ers 3.933906555175781e-06
▁eager 3.00390625
ly 9.715557098388672e-05
▁await 0.1771240234375
▁the 0.0950927734375
▁init 9.3828125
iation 1.3947486877441406e-05
▁of 0.0216827392578125
▁clin 2.0859375
ical 5.793571472167969e-05
▁tri 0.017333984375
als 1.1920928955078125e-06
, 0.349365234375
▁the 0.96630859375
▁potential 5.8671875
▁impact 1.841796875
▁of 0.0888671875
▁Ch 3.04296875
iros 0.0013217926025390625
cience 0.00010442733764648438
' 1.259765625
s 0.000274658203125
▁dedic 8.9296875
ation 8.14199447631836e-05
▁and 1.0615234375
▁innov 0.86376953125
ation 0.34423828125
▁cannot 1.658203125
▁be 0.0006580352783203125
▁under 1.7080078125
st 0.3056640625
ated 5.602836608886719e-06
. 0.1390380859375
